Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gp140 + aluminum phosphate
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
gp140 + aluminum phosphate is a combination vaccine component consisting of the recombinant HIV-1 envelope glycoprotein gp140 formulated with **aluminum phosphate** as an adjuvant. Gp140 is a stabilized form of the HIV-1 envelope protein, designed to elicit immune responses against HIV. Aluminum phosphate serves as an immunologic adjuvant to enhance the magnitude and durability of the immune response, particularly promoting antibody (Th2-type) responses to the protein antigen. This formulation has been studied as part of heterologous prime-boost regimens for the prevention of HIV-1 infection, often in combination with other vaccine components such as adenovirus-vectored vaccines. It does not have a single developer-associated brand name, but the formulation has been researched and trialed primarily by** Janssen Vaccines & Prevention B.V.**
- Other names
- Clade C gp140 + aluminum phosphateMosaic gp140 + aluminum phosphate
02
Targets
gp140 (HIV-1 gp140)
Beyond the preview
Go deeper on gp140 + aluminum phosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gp140 + aluminum phosphate.